Founded in 2011 by ex-Pfizer R&D executives and healthcare investors, Thetis Pharmaceuticals LLC is a biopharmaceutical company developing novel small molecule drugs for the treatment of GI diseases.
Using our proprietary HEALER™ platform technology, Thetis transforms endogenous lipids with established efficacy into novel salts to overcome the formulation and IP hurdles that have limited the development of bioactive lipids as pharmaceutical drugs in the GI arena. Our drug candidates have unique mechanisms of action compared to existing therapeutic agents, and prospects for abbreviated non-clinical and clinical development programs. They are new molecular entities with strong composition of matter protection.
We are pursuing development of our lead candidate TP-252 for the treatment of ulcerative colitis. This focus is based on independent Phase II clinical data showing that the active agent in TP-252 helps maintain remission in ulcerative colitis patients who are at increased risk of relapse. Thetis expects to begin Phase I clinical trials in 2018.
In addition, the active agent in TP-252 has been shown in randomized clinical studies to be effective in the treatment of familial adenomatous polyposis (FAP), a rare genetic disorder. Thetis has been granted orphan drug designation for TP-252 for the treatment of FAP, and is in discussions with FDA on the design of the clinical development program.
Beyond TP-252, Thetis has initiated an exploratory program based on application of its platform technology to a class of bioactive lipids known as Specialized Proresolving Mediators (SPMs), which are potent metabolites of omega-3 and omega-6 polyunsaturated fatty acids. SPMs are naturally occurring lipid molecules that regulate and trigger inflammation resolution pathways, and offer a novel approach for inducing and maintaining remission in patients with IBD. The initial focus of our SPM-based candidate, TP-317, is on an orphan disease in IBD.